Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma; ODM derived from:


Versions (1) ▾
  1. 12/13/19
Copyright Holder:
Uploaded on:

December 13, 2019

No DOI assigned. To request one please log in.
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Esophageal Carcinoma NCT01034683

Eligibility Esophageal Carcinoma NCT01034683

Inclusion Criteria
histologically proven squamous cell carcinoma of the esophagus(include cardiac cancer)
newly diagnosed patients should be unable or unwilling to surgery
recurrence after surgery must have no adjuvant chemotherapy or radiotherapy are allowed
patients are required to have dimensionally measurable disease,with an objective measurable focus:preferably the use of spiral computed tomography(ct)and measurements of maximum diameter≥1cm.
cooperative oncology group performance status 0-2 or kps score ≥60,survival time ≥3 months
neutrophils(anc)≥1.5×109/l; blood platelets counts(bpc)≥80×109/l
hemoglobin(hgb)≥90g/l ,serum total bilirubin ≤1.0 times the upper normal limit(uln): alanine aminotransferase and glutamic-oxalacetic transaminase (alt and ast)≤2.5 uln
serum creatinine (cr)≤1.5uln
Exclusion Criteria
pregnant or nursing women;
female patients at child-bearing age, without taking effective contraceptive methods;
patients who have pathologic confirmation of other types of tumors (eg, leiomyosarcoma, malignant lymphoma) rather than esophageal cancer;
patients with tumors other than esophageal cancer ,except cervical carcinoma in situ and skin basal cancer or squamous cell carcinoma received adequate treatment;
patients with cerebral or meningeal metastasis, intestinal obstruction, or symptomatic pathologic changes of peripheral nerve,ncic-ctg standard >grade 2
patients with serious complications such as: serious heart disease remained unstable after treatment, or myocardial infarction, congestive heart failure, unstable angina, frank pericardial effusion or unstable arrhythmias in 6 months before being enrolled into the group; confirmed neuropathy or psychosis, including dementia or epilepsia; uncontrolled infection;active disseminated intravascular coagulation;uncontrolled diabetes, fasting serum glucose> 7.8mmol / l